Optic Nerve Sheath Fenestration for Progressive Visual Loss in Cerebral Venous Sinus Thrombosis: A Long-Term Retrospective Study
Zong-Shan Li,Lu Cheng,Yang Xu,Qiao Sun,Jian Zhang,Lin Bai,Ting Feng,Song Tan,Huan Wang,Bo-Lin Deng,Qiang Li,Ya-Xing Gui,Hui Chen
DOI: https://doi.org/10.2139/ssrn.4147528
2022-01-01
SSRN Electronic Journal
Abstract:Background: Cerebral venous sinus thrombosis (CVST), a cerebrovascular disease, predominantly affects young individuals. Progressive CVST-induced visual loss remains problematic, despite decreasing overall mortality owing to early diagnosis and aggressive treatment. Optic nerve sheath fenestration (ONSF) improves or stabilizes visual function in patients with idiopathic intracranial hypertension; however, its role in CVST awaits elucidation. We aimed to evaluate ONSF's efficacy and safety in resolving CVST-induced visual impairment using long-term observation. Methods: This retrospective study included 18 ONSF-treated patients with progressive CVST-induced visual loss between 2012 and 2021. All patients received maximum medical therapy, including anticoagulants and intracranial pressure-lowering medications. The main outcome measures included best-corrected visual acuity (BCVA), visual fields (VFs), and optic nerve head, which were assessed preoperatively, 1 week and over-six months postoperatively. Activities of daily living (ADL) and National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) scores were assessed upon final follow-up. Findings: Thirty-one ONSF-treated eyes of 18 patients were included. The mean follow-up duration was 35·6 months (range, 1 week–8 years). Two patients were lost to follow-up. Postoperative BCVA remained stable/improved in 25/31 eyes (80·6%) 1 week postoperatively and 17/28 eyes (60·7%) upon final follow-up. Of the 10 eyes of seven patients with available VFs, one eye (10%) exhibited improved VFs and eight (80%) preserved postoperative VFs. All papilledema resolved postoperatively. No complications were reported except one transient postoperative diplopia. The median ADL score was 100 (range, 25–100) and mean total VFQ-25 score 40·6 (range, 9·5–87·3). Interpretation: This was the largest study involving long-term follow-up to describe ONSF's role in CVST. Considering its favorable efficacy and safety, ONSF can be regarded a potentially important approach to resolving progressive visual loss in CVST patients, in conjunction with anti-coagulation and ICP-lowering therapy.Funding Information: This study was funded by the National Basic Research Program of China (973 Program, No. 2015CB554103), Department of Science and Technology of Sichuan Province, China (2020YFSY0044), the Natural Science Foundation of Shanghai (22ZR1449800), National Natural Science Foundation of China (81271035, 81401038 and 82000880).Declaration of Interests: All authors declare no competing interests.Ethics Approval Statement: This study was reviewed and approved by the Medical Ethical Committee of the Shanghai General Hospital.